🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million infections per year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.

“This approval signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Results and Worldwide Availability

As per data published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have expressed positive views. Having a easy-to-administer therapy such as this is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.